newsfilter
← Latest News
Business Wire·

Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS

In a weekly cohort of 4,754 newly hospitalized patients, addition of lenzilumab to standard of care (SOC) could result in over £5.5 million in cost savings weekly1 Lenzilumab plus SOC resulted in per‑patient cost savings between £8,462 and £1